•New data supports omega-3s for glaucoma in DED patients•Aldeyra to formally appeal third reproxalap CRL•Merck releases phase 2b/3 wet AMD data for tri-specific antibody•Study finds routine dilation appears safe as angle-closure stays rare•Academy in Anaheim: optometry research, product, and innovations•New data supports omega-3s for glaucoma in DED patients•Aldeyra to formally appeal third reproxalap CRL•Merck releases phase 2b/3 wet AMD data for tri-specific antibody•Study finds routine dilation appears safe as angle-closure stays rare•Academy in Anaheim: optometry research, product, and innovations
HEADLINES
FEATURED
Phase 3 4SIGHT trial has begun enrolling patients and 2-year phase 2 SPECTRA results show over 60% treatment burden reduction.
Earn FREE CE 24/7 with Courses by Eyes On Eyecare
Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.
